CD274 and neoplasm: In Europe, EMA restricts the use of pembrolizumab and atezolizumab in first line mUC to cisplatin-ineligible patients with PD-L1 overexpression (CPS ≥10% in case of pembrolizumab and tumor expression PD-L1 of ≥5% for atezolizumab).